PLSE vs. IRMD, SPNE, UTMD, ARAY, CTSO, NARI, IRTC, ICUI, NVCR, and IART
Should you be buying Pulse Biosciences stock or one of its competitors? The main competitors of Pulse Biosciences include Iradimed (IRMD), SeaSpine (SPNE), Utah Medical Products (UTMD), Accuray (ARAY), Cytosorbents (CTSO), Inari Medical (NARI), iRhythm Technologies (IRTC), ICU Medical (ICUI), NovoCure (NVCR), and Integra LifeSciences (IART). These companies are all part of the "surgical & medical instruments" industry.
Pulse Biosciences (NASDAQ:PLSE) and Iradimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership.
Iradimed received 4 more outperform votes than Pulse Biosciences when rated by MarketBeat users. However, 65.17% of users gave Pulse Biosciences an outperform vote while only 64.69% of users gave Iradimed an outperform vote.
Iradimed has a consensus price target of $62.50, suggesting a potential upside of 47.16%. Given Iradimed's higher probable upside, analysts plainly believe Iradimed is more favorable than Pulse Biosciences.
Iradimed has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
In the previous week, Pulse Biosciences had 3 more articles in the media than Iradimed. MarketBeat recorded 5 mentions for Pulse Biosciences and 2 mentions for Iradimed. Iradimed's average media sentiment score of 1.43 beat Pulse Biosciences' score of 0.58 indicating that Iradimed is being referred to more favorably in the news media.
Pulse Biosciences has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 92.3% of Iradimed shares are held by institutional investors. 71.5% of Pulse Biosciences shares are held by insiders. Comparatively, 42.6% of Iradimed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Iradimed has a net margin of 26.48% compared to Pulse Biosciences' net margin of 0.00%. Iradimed's return on equity of 24.63% beat Pulse Biosciences' return on equity.
Summary
Iradimed beats Pulse Biosciences on 12 of the 17 factors compared between the two stocks.
Get Pulse Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulse Biosciences Competitors List
Related Companies and Tools
